epirubicin has been researched along with Asthenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davies, A; Gandara, D; Huynh, M; Johl, J; Lara, P; Lau, D; Tanaka, M | 1 |
| Li, T; Li, ZW; Wen, HC | 1 |
2 trial(s) available for epirubicin and Asthenia
| Article | Year |
|---|---|
Population-based phase I trial of irinotecan and epirubicin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Drug Synergism; Epirubicin; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Topoisomerase I Inhibitors | 2008 |
[Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer].
Topics: Adjuvants, Immunologic; Adult; Aged; Asthenia; CD4-Positive T-Lymphocytes; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Fever; Fluorouracil; Humans; Iodized Oil; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Survival Rate; Thymopentin | 2007 |